solifenacin succinate has been researched along with Asialia in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, T; Caldwell, P; Lai, E; Raman, G; Tunnicliffe, D | 1 |
| Bai, B; Lei, Y; Mu, J; Wang, J; Zhang, T; Zhang, X | 1 |
| Choi, WS; Chung, H; Kim, HG; Paick, SH; Park, HK; Yang, DY; Yang, SK | 1 |
| Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M | 1 |
| Li, J; Li, P; Liu, B; Wang, Y; Wu, Y | 1 |
| Cheon, SY; Cho, SY; Choi, JB; Choo, MS; Chun, JY; Kim, JC; Kim, JH; Lee, KS; Oh, SJ; Park, J; Seo, JT; Song, M | 1 |
| Huang, W; Zhang, Y; Zhou, X; Zong, H | 1 |
| Hsiao, SM; Kuo, HC; Lin, HH | 1 |
| Besuyen, R; Bolduc, S; Bosman, B; Dahler, E; Hollestein-Havelaar, A; Newgreen, D; Rittig, S; Sawyer, W | 1 |
| Cho, WY; Chung, JM; Kang, DI; Lee, SD; Park, S; Ryu, DS | 1 |
| Barkin, J; Carlson, K; Drutz, H; Egerdie, B; Gajewski, JB; Herschorn, S; Paradiso-Hardy, F; Pommerville, P; Radomski, S; Schulz, J; Stothers, L | 1 |
| Brubaker, L; Khandwala, S; Lowder, J; Meikle, SF; Menefee, SA; Nolen, TL; Nygaard, I; Paraiso, MF; Richter, HE; Schaffer, J; Sirls, L; Spino, C; Visco, AG; Wallace, D | 1 |
| Fukumoto, K; Hara, R; Koide, T; Miyaji, Y; Nagai, A; Yokoyama, T | 1 |
| Sand, PK | 1 |
| Cardozo, L; Chapple, C; Haab, F; Ridder, AM | 1 |
| Garely, AD; Lucente, V; Smith, N; Vapnek, J | 1 |
| Gotoh, M; Ishizuka, O; Itoh, N; Kakizaki, H; Marui, E; Okada, H; Ozono, S; Seki, N; Sugiyama, T; Yamaguchi, O; Yokota, T; Yoshida, M | 1 |
5 review(s) available for solifenacin succinate and Asialia
| Article | Year |
|---|---|
Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review.
Topics: Adolescent; Child; Cholinergic Antagonists; Constipation; Humans; Muscarinic Antagonists; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Xerostomia | 2023 |
The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Drug Therapy, Combination; Flank Pain; Health Status; Hematuria; Humans; Lower Urinary Tract Symptoms; Muscarinic Antagonists; Postoperative Complications; Quality of Life; Solifenacin Succinate; Stents; Sulfonamides; Tamsulosin; Ureter; Xerostomia | 2017 |
[Comparisons of therapeutic efficacy and safety of solifenacin versus tolterodine in patients with overactive bladder: a meta-analysis of outcomes].
Topics: Benzhydryl Compounds; Constipation; Cresols; Humans; Phenylpropanolamine; Quinuclidines; Safety; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Xerostomia | 2014 |
Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis.
Topics: Adult; Benzilates; Constipation; Humans; Imidazoles; Randomized Controlled Trials as Topic; Solifenacin Succinate; Urinary Bladder, Overactive; Urological Agents; Xerostomia | 2015 |
Elevating our therapeutic expectations in overactive bladder.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Constipation; Cresols; Delayed-Action Preparations; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Incontinence; Vision Disorders; Xerostomia | 2004 |
10 trial(s) available for solifenacin succinate and Asialia
| Article | Year |
|---|---|
Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder.
Topics: Acetylcholine; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Solifenacin Succinate; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Xerostomia; Young Adult | 2019 |
Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Benzilates; Blood Pressure; Constipation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Nasopharyngitis; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Xerostomia | 2019 |
Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial.
Topics: Adolescent; Child; Child, Preschool; Constipation; Double-Blind Method; Female; Humans; Male; Muscarinic Antagonists; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Xerostomia | 2017 |
Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study.
Topics: Asian People; Child; Child, Preschool; Drug Tolerance; Fatigue; Female; Humans; Male; Prospective Studies; Republic of Korea; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents; Xerostomia | 2017 |
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Topics: Adult; Aged; Aged, 80 and over; Canada; Chi-Square Distribution; Double-Blind Method; Drug Administration Schedule; Female; Humans; Incidence; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Xerostomia | 2010 |
Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.
Topics: Aged; Benzilates; Botulinum Toxins, Type A; Cholinergic Antagonists; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Linear Models; Middle Aged; Nortropanes; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Incontinence, Urge; Urinary Retention; Urinary Tract Infections; Xerostomia | 2012 |
Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study.
Topics: Aged; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Xerostomia | 2013 |
Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
Topics: Constipation; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Patient Satisfaction; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Time; Treatment Outcome; Urinary Incontinence; Vision Disorders; Xerostomia | 2005 |
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Visual Acuity; Xerostomia | 2007 |
Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Topics: Adult; Aged; Benzilates; Constipation; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Xerostomia | 2007 |
3 other study(ies) available for solifenacin succinate and Asialia
| Article | Year |
|---|---|
A prospective, observational study to assess the association between dry mouth and solifenacin treatment in patients with overactive bladder syndrome.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Xerostomia; Young Adult | 2015 |
Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Severity of Illness Index; Solifenacin Succinate; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Vision Disorders; Xerostomia; Young Adult | 2018 |
Solifenacin and darifenacin for overactive bladder.
Topics: Benzofurans; Drug Interactions; Humans; Intestinal Obstruction; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Incontinence; Xerostomia | 2005 |